NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors
ConclusionThese data suggest that combinational treatment with NK cell–based immunotherapy and cetuximab may be promising for patients with TKI-resistant NSCLC.
Source: Cytotherapy - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Cytology | Erbitux | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva